Archive

Dive into a collection of past posts and rediscover timeless content.

Why dual- and triple-agonists outperform semaglutide

Why dual- and triple-agonists outperform semaglutide

It’s not “stronger.” It’s wider signal coverage.

Feb 8, 2026

GLP-1s didn’t change fat loss. They changed fuel selection.

GLP-1s didn’t change fat loss. They changed fuel selection.

Feb 7, 2026

Repair peptides aren’t upgrades

Repair peptides aren’t upgrades

They fix damage. They don’t raise the ceiling.

Feb 6, 2026

“Research use only” doesn’t mean what you think

“Research use only” doesn’t mean what you think

The FDA just made that painfully clear.

Feb 5, 2026

Why Peptides Fail Without Context

Why Peptides Fail Without Context

Most peptide failures aren’t about the peptide

Feb 3, 2026